Assessment of the treatment efficacy of Terbinafine and Griseofulvin in treating the childhood fungal infections affecting the scalp and correlating it both with clinical and mycological aspects.

ASSESSMENT OF THE THERAPEUTIC EFFICACY OF TERBINAFINE AND GRISEOFULVIN IN CHILDREN WITH TINEA CAPITIS ALONG WITH CLINICOMYCOLOGICAL CORRELATION - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/091245

Enrollment

Registered

2025-07-21

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B350- Tinea barbae and tinea capitis

Interventions

Intervention1: TERBINAFINE: Based on body weight, For people weighing 10-20 kg ,62.5 mg once in a day taken orally for 4 weeks. For people weighing 20-40 kg, 125 mg once in a day taken orally for 4 we

Eligibility

Inclusion criteria

Inclusion criteria: Potassium hydroxide(KOH) wet mount positive cases of tinea capitis, Age group : greater than or equal to 2 years and lesser than or equal to 18 years of age, Patients who are willing to be enrolled in the study

Exclusion criteria

Exclusion criteria: Patients who have taken any oral or topical antifungal therapy within four weeks prior to inclusion in the study, Hepatic disease, Renal disease, Allergy to Griseofulvin and Terbinafine

Design outcomes

Primary

Measure	Time frame
Assessment of therapeutic efficacy of Terbinafine and GriseofulvinTimepoint: 1 year	—

Secondary

Measure	Time frame
Identification of species causing Tinea capitisTimepoint: 1 year	—

Countries

India

Contacts

Public ContactDr R Madhu

Madras medical college

renmadhu08@gmail.com9344622731

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026